Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study

A. M. Pellicelli, V. Pace Palitti, P. Vignally, F. Ceccherini-Silberstein, M. Siciliano, V. Giannelli, A. Moretti, P. Tarquini, G. Scifo, V. Messina, A. Ascione, A. Izzi, M. Marignani, C. D'Ambrosio, L. Fondacaro, G. M. Ettorre, P. Ialongo, R. Sacco, C. F. Perno, G. Barbarini & 1 others CLEO Group

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

BACKGROUND & AIMS: The proportion of HCV-infected patients over age 65 years in Western countries is increasing. This growth and the advent of new antiviral therapy bring into the question the real-world efficacy and safety of the combination of sofosbuvir (SOF) and simeprevir (SMV) plus a flat dose of 800 mg/d ribavirin (RBV) in elderly patients with cirrhosis compared to younger patients. METHODS: Retrospective observational multicentre real-life investigation study of SOF/SMV/RBV for a duration of 12 weeks in HCV genotype 1-infected patients with cirrhosis. RESULTS: Of the 270 patients enrolled in this study, with compensated cirrhosis, 133 (49.2%) were >/=65 years of age. Sustained virological response at 12 weeks (SVR12) was achieved by 94.2% (129/137) of those aged /=65 years. Diabetes was the most common comorbidity in patients >/=65 years compared to younger patients (26.3% vs 12.4% P
Original languageEnglish
Pages (from-to)653-661
Number of pages9
JournalLiver International
Volume37
Issue number5
DOIs
Publication statusPublished - May 1 2017

Fingerprint

Ribavirin
Genotype
Safety
Fibrosis
Sofosbuvir
Simeprevir
Antiviral Agents
Comorbidity
Growth

Keywords

  • cirrhosis
  • elderly
  • genotype 1
  • hepatitis C
  • simeprevir
  • sofosbuvir

Cite this

Pellicelli, A. M., Palitti, V. P., Vignally, P., Ceccherini-Silberstein, F., Siciliano, M., Giannelli, V., ... Group, CLEO. (2017). Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study. Liver International, 37(5), 653-661. https://doi.org/10.1111/liv.13288 [doi]

Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study. / Pellicelli, A. M.; Palitti, V. Pace; Vignally, P.; Ceccherini-Silberstein, F.; Siciliano, M.; Giannelli, V.; Moretti, A.; Tarquini, P.; Scifo, G.; Messina, V.; Ascione, A.; Izzi, A.; Marignani, M.; D'Ambrosio, C.; Fondacaro, L.; Ettorre, G. M.; Ialongo, P.; Sacco, R.; Perno, C. F.; Barbarini, G.; Group, CLEO.

In: Liver International, Vol. 37, No. 5, 01.05.2017, p. 653-661.

Research output: Contribution to journalArticle

Pellicelli, AM, Palitti, VP, Vignally, P, Ceccherini-Silberstein, F, Siciliano, M, Giannelli, V, Moretti, A, Tarquini, P, Scifo, G, Messina, V, Ascione, A, Izzi, A, Marignani, M, D'Ambrosio, C, Fondacaro, L, Ettorre, GM, Ialongo, P, Sacco, R, Perno, CF, Barbarini, G & Group, CLEO 2017, 'Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study', Liver International, vol. 37, no. 5, pp. 653-661. https://doi.org/10.1111/liv.13288 [doi]
Pellicelli AM, Palitti VP, Vignally P, Ceccherini-Silberstein F, Siciliano M, Giannelli V et al. Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study. Liver International. 2017 May 1;37(5):653-661. https://doi.org/10.1111/liv.13288 [doi]
Pellicelli, A. M. ; Palitti, V. Pace ; Vignally, P. ; Ceccherini-Silberstein, F. ; Siciliano, M. ; Giannelli, V. ; Moretti, A. ; Tarquini, P. ; Scifo, G. ; Messina, V. ; Ascione, A. ; Izzi, A. ; Marignani, M. ; D'Ambrosio, C. ; Fondacaro, L. ; Ettorre, G. M. ; Ialongo, P. ; Sacco, R. ; Perno, C. F. ; Barbarini, G. ; Group, CLEO. / Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study. In: Liver International. 2017 ; Vol. 37, No. 5. pp. 653-661.
@article{7e079a2a38824b60973bebe247ae3871,
title = "Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study",
abstract = "BACKGROUND & AIMS: The proportion of HCV-infected patients over age 65 years in Western countries is increasing. This growth and the advent of new antiviral therapy bring into the question the real-world efficacy and safety of the combination of sofosbuvir (SOF) and simeprevir (SMV) plus a flat dose of 800 mg/d ribavirin (RBV) in elderly patients with cirrhosis compared to younger patients. METHODS: Retrospective observational multicentre real-life investigation study of SOF/SMV/RBV for a duration of 12 weeks in HCV genotype 1-infected patients with cirrhosis. RESULTS: Of the 270 patients enrolled in this study, with compensated cirrhosis, 133 (49.2{\%}) were >/=65 years of age. Sustained virological response at 12 weeks (SVR12) was achieved by 94.2{\%} (129/137) of those aged /=65 years. Diabetes was the most common comorbidity in patients >/=65 years compared to younger patients (26.3{\%} vs 12.4{\%} P",
keywords = "cirrhosis, elderly, genotype 1, hepatitis C, simeprevir, sofosbuvir",
author = "Pellicelli, {A. M.} and Palitti, {V. Pace} and P. Vignally and F. Ceccherini-Silberstein and M. Siciliano and V. Giannelli and A. Moretti and P. Tarquini and G. Scifo and V. Messina and A. Ascione and A. Izzi and M. Marignani and C. D'Ambrosio and L. Fondacaro and Ettorre, {G. M.} and P. Ialongo and R. Sacco and Perno, {C. F.} and G. Barbarini and CLEO Group",
note = "LR: 20170428; CI: (c) 2016; JID: 101160857; OTO: NOTNLM; 2016/03/24 00:00 [received]; 2016/10/21 00:00 [accepted]; 2016/10/27 06:00 [pubmed]; 2016/10/27 06:00 [medline]; 2016/10/27 06:00 [entrez]; ppublish",
year = "2017",
month = "5",
day = "1",
doi = "10.1111/liv.13288 [doi]",
language = "English",
volume = "37",
pages = "653--661",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "5",

}

TY - JOUR

T1 - Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study

AU - Pellicelli, A. M.

AU - Palitti, V. Pace

AU - Vignally, P.

AU - Ceccherini-Silberstein, F.

AU - Siciliano, M.

AU - Giannelli, V.

AU - Moretti, A.

AU - Tarquini, P.

AU - Scifo, G.

AU - Messina, V.

AU - Ascione, A.

AU - Izzi, A.

AU - Marignani, M.

AU - D'Ambrosio, C.

AU - Fondacaro, L.

AU - Ettorre, G. M.

AU - Ialongo, P.

AU - Sacco, R.

AU - Perno, C. F.

AU - Barbarini, G.

AU - Group, CLEO

N1 - LR: 20170428; CI: (c) 2016; JID: 101160857; OTO: NOTNLM; 2016/03/24 00:00 [received]; 2016/10/21 00:00 [accepted]; 2016/10/27 06:00 [pubmed]; 2016/10/27 06:00 [medline]; 2016/10/27 06:00 [entrez]; ppublish

PY - 2017/5/1

Y1 - 2017/5/1

N2 - BACKGROUND & AIMS: The proportion of HCV-infected patients over age 65 years in Western countries is increasing. This growth and the advent of new antiviral therapy bring into the question the real-world efficacy and safety of the combination of sofosbuvir (SOF) and simeprevir (SMV) plus a flat dose of 800 mg/d ribavirin (RBV) in elderly patients with cirrhosis compared to younger patients. METHODS: Retrospective observational multicentre real-life investigation study of SOF/SMV/RBV for a duration of 12 weeks in HCV genotype 1-infected patients with cirrhosis. RESULTS: Of the 270 patients enrolled in this study, with compensated cirrhosis, 133 (49.2%) were >/=65 years of age. Sustained virological response at 12 weeks (SVR12) was achieved by 94.2% (129/137) of those aged /=65 years. Diabetes was the most common comorbidity in patients >/=65 years compared to younger patients (26.3% vs 12.4% P

AB - BACKGROUND & AIMS: The proportion of HCV-infected patients over age 65 years in Western countries is increasing. This growth and the advent of new antiviral therapy bring into the question the real-world efficacy and safety of the combination of sofosbuvir (SOF) and simeprevir (SMV) plus a flat dose of 800 mg/d ribavirin (RBV) in elderly patients with cirrhosis compared to younger patients. METHODS: Retrospective observational multicentre real-life investigation study of SOF/SMV/RBV for a duration of 12 weeks in HCV genotype 1-infected patients with cirrhosis. RESULTS: Of the 270 patients enrolled in this study, with compensated cirrhosis, 133 (49.2%) were >/=65 years of age. Sustained virological response at 12 weeks (SVR12) was achieved by 94.2% (129/137) of those aged /=65 years. Diabetes was the most common comorbidity in patients >/=65 years compared to younger patients (26.3% vs 12.4% P

KW - cirrhosis

KW - elderly

KW - genotype 1

KW - hepatitis C

KW - simeprevir

KW - sofosbuvir

U2 - 10.1111/liv.13288 [doi]

DO - 10.1111/liv.13288 [doi]

M3 - Article

VL - 37

SP - 653

EP - 661

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 5

ER -